Dyne Therapeutics Inc
DYN14.220USD
+0.980+7.40%
종가 09/05, 16:00（ET）시세는 15분 지연됩니다
1.63B시가총액
손실P/E TTM
자세한 내용은 Dyne Therapeutics Inc 회사
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
회사 정보
종목 코드 DYN
회사 이름Dyne Therapeutics Inc
상장일Sep 17, 2020
CEOMr. John Cox
직원 수191
유형Ordinary Share
회계 연도 종료Sep 17
주소1560 Trapelo Road
도시WALTHAM
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02451
전화17817868230
웹사이트https://dyne-tx.com/
종목 코드 DYN
상장일Sep 17, 2020
CEOMr. John Cox
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, Aug 15
마지막 업데이트: Fri, Aug 15
주주
주주 유형
주주
주주
비율
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
기타
66.64%
주주
주주
비율
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
기타
66.64%
주주 유형
주주
비율
Investment Advisor
29.03%
Investment Advisor/Hedge Fund
24.17%
Venture Capital
21.19%
Hedge Fund
13.77%
Private Equity
3.36%
Research Firm
2.61%
Individual Investor
0.59%
Bank and Trust
0.28%
Pension Fund
0.19%
기타
4.79%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
433
126.04M
90.68%
+6.43M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.72M
1.97%
+1.37M
+101.71%
Mar 31, 2025
TCG Crossover Management, LLC
2.65M
1.92%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Sep 2
마지막 업데이트: Tue, Sep 2
이름
비율
iShares Neuroscience and Healthcare ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Health Innovation Active ETF
0.11%
iShares Biotechnology ETF
0.09%
Optimize Strategy Index ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
더 보기
iShares Neuroscience and Healthcare ETF
비율2.06%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.8%
SPDR S&P Biotech ETF
비율0.27%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.18%
ProShares Ultra Nasdaq Biotechnology
비율0.12%
Invesco Nasdaq Biotechnology ETF
비율0.11%
iShares Health Innovation Active ETF
비율0.11%
iShares Biotechnology ETF
비율0.09%
Optimize Strategy Index ETF
비율0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
비율0.07%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
